Last reviewed · How we verify
Single Dose of Hydroxychloroquine
Hydroxychloroquine is an antimalarial and immunomodulatory agent that inhibits toll-like receptor signaling and reduces inflammatory cytokine production.
Hydroxychloroquine is an antimalarial and immunomodulatory agent that inhibits toll-like receptor signaling and reduces inflammatory cytokine production. Used for Malaria, Systemic lupus erythematosus (SLE), Rheumatoid arthritis.
At a glance
| Generic name | Single Dose of Hydroxychloroquine |
|---|---|
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Drug class | Antimalarial immunomodulator |
| Target | Toll-like receptors (TLR); lysosomal pH modulation |
| Modality | Small molecule |
| Therapeutic area | Immunology; Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Hydroxychloroquine accumulates in lysosomes and endosomes, raising their pH and interfering with antigen presentation and toll-like receptor activation. This suppresses the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-17, making it effective in treating autoimmune and inflammatory conditions. It also has weak anticoagulant properties and may reduce thrombotic events.
Approved indications
- Malaria
- Systemic lupus erythematosus (SLE)
- Rheumatoid arthritis
- Sjögren's syndrome
Common side effects
- Retinopathy
- Gastrointestinal disturbance (nausea, diarrhea)
- Headache
- Pruritus
- Cardiomyopathy (rare, with long-term use)
Key clinical trials
- A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies (PHASE1)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) (PHASE2)
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- A Study of TIL in Advanced Solid Tumors (CZ) (PHASE1)
- A Study of GC203 TIL in PDCA (RJ) (EARLY_PHASE1)
- A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital) (EARLY_PHASE1)
- A Study of TIL in Advanced Solid Tumors (DFGD) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: